> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Extends Review Timeline for Orca Bio’s Cell Therapy Orca-T
- URL: https://www.fdaweb.com/fda-extends-review-timeline-for-orca-bios-cell-therapy-orca-t/
- Published: 2026-04-01T12:00:00.000Z
- Updated: 2026-09-14T13:36:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160916

FDA has extended by three months its review of an Orca Bio BLA for its experimental cell therapy Orca-T, pushing the agency’s decision deadline to 7/6\. The submission is seeking approval for the therapy to treat a range of hematologic malignancies, including acute leukemias and myelodysplastic syndromes.

According to the company, the extension was triggered after it submitted updated chemistry, manufacturing and controls information in response to FDA requests. The agency classified the submission as a “major amendment,” a designation that typically adds three months to the review clock under the Prescription Drug User Fee Act.

Orca Bio notes that FDA has not asked for additional clinical data, signaling that the delay is related to manufacturing and technical documentation rather than questions about the therapy’s efficacy or safety profile. The company says it does not expect the new information to alter the benefit-risk assessment of the therapy.

Orca-T is described as an allogeneic T-cell immunotherapy designed to improve outcomes for patients undergoing hematopoietic stem cell transplantation. The therapy uses a precisely defined mix of donor-derived immune cells — including hematopoietic stem cells, regulatory T cells and conventional T cells — aimed at reducing complications such as graft-versus-host disease while preserving anti-cancer effects.

If approved, Orca-T could represent a novel approach in the evolving field of cell therapies for blood cancers, particularly in the transplant setting where balancing efficacy and immune-related toxicity remains a central challenge.